Matinas BioPharma Holdings, Inc. (MTNB) Stock: Here’s Why It’s Headed Up


Matinas BioPharma Holdings, Inc. (MTNB) is headed up in the market today. The stock, focused in the biotech industry, is presently trading at $0.71 after heading up 8.39% so far in today’s session. As it relates to biotech stocks, there are several factors that have the ability to generate movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines relating to MTNB:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-13-19 08:05AM Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Tops Revenue Estimates
06:45AM Matinas BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update
06:30AM Matinas Biopharma Holdings, Inc. to Host Earnings Call
Aug-06-19 10:30AM Will Matinas Biopharma Holdings, Inc. (MTNB) Report Negative Earnings Next Week? What You Should Know
Jul-30-19 07:30AM Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2019 Operational and Financial Results on August 13, 2019

Nonetheless, any time investors are making a decision to invest, investors should take a look at much more than just news, especially in the speculative biotech sector. Here’s what’s happing when it comes to Matinas BioPharma Holdings, Inc..

Recent Movement From MTNB

Although a move toward the top in a single session, like the move that we’re seeing from Matinas BioPharma Holdings, Inc. may make some investors jump for joy, a single session move by itself should not be the reason for a decision to, or not to, buy a company’s stock. It’s always important to dig into trends experienced by the stock further out than a single trading day. As it relates to MTNB, here are the trends that we’ve seen:

  • Past 5 Trading Sessions – Throughout the past seven days, MTNB has produced a change in price in the amount of -0.52%.
  • Monthly – The return from Matinas BioPharma Holdings, Inc. throughout the past month works out to -16.82%.
  • Past Three Months – In the last 3 months, the company has generated a return on investment that works out to -24.97%
  • Past Six Months – Throughout the previous six months, investors have seen a performance that equates to -33.50% from the stock.
  • Year To Date – Since the the last trading session of last year MTNB has generated a return of 19.58%.
  • Full Year – Lastly, throughout the last year, we have seen movement in the amount of 92.19% out of MTNB. In this period, the stock has sold at a high price of -52.57% and a low of 100.42%.

Important Ratios

Digging into a few ratios associated with a company can give prospective investors an understanding of how risky and/or potentially profitable a pick may be. Below are a few of the most important ratios to think about when looking at MTNB.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors have a belief that the value of the stock is going to go down. In general, biotechnology stocks tend to have a higher short ratio. However, we also see quite a few short squeezes in the space. Nonetheless, in relation to Matinas BioPharma Holdings, Inc., the stock’s short ratio amounts to 6.33.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Basically, they measure whether or not a company can pay its debts when they mature based on quick assets or current assets. Because many biotech several companies rely heavily on the continuation of investor support, the current and quick ratios can seem damning. Nonetheless, several good picks in the biotechnology space come with strong quick and current ratios. When it comes to MTNB, the quick and current ratios total up to 12.80 and 12.80 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the book value of assets owned by the company. as it relates to Matinas BioPharma Holdings, Inc., that ratio comes in at 0.28.

Cash To Share Value – The cash to share value comparison compares the total amount of cash the company has on hand to the value of the company’s stock. Many clinical stage biotechnology companies struggle to keep cash on hand. So, if you’re interested in a stock in the biotech space, this is an important ratio to think about. In this case, the cash to share value ratio works out to 0.27.

Analyst Opinions With Regard To Matinas BioPharma Holdings, Inc.

While it’s not a smart idea to unknowingly follow the opinions of analysts, it is a good idea to use their thoughts to validate your own opinions before making an investment decision in the biotechnology space. Below are the recent moves that we’ve seen from analysts as it relates to MTNB.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-26-19 Initiated H.C. Wainwright Buy $4

What Are Big Money Players Doing With Matinas BioPharma Holdings, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in MTNB, here’s what we’re seeing:

Institutions own 25.70% of the company. Institutional interest has moved by -0.18% over the past three months. When it comes to insiders, those who are close to the company currently own 1.90% percent of MTNB shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

What’s The Float Looking Like?

Traders tend to be interested in the total numbers of shares both available and outstanding. In regard to Matinas BioPharma Holdings, Inc., currently there are 146.19M with a float of 124.22M. These data mean that out of the total of 146.19M shares of MTNB in existence today, 124.22M are able to be traded in the public space.

I also like to dig into the short percent. After all, if a high portion of the float available for trading is sold short, the overall feeling among traders is that the stock is headed for a dive. When it comes to MTNB, the short percentage of the float totals up to 3.66%. Most traders believe that a concerning short percent of the float is any percentage over 40%. Through my work, I’ve found that anything over 26% is probably going to be a play that comes with hefty risk.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.16. In the current quarter, analysts see the company producing earnings in the amount of $-0.04. Over the last 5 years, MTNB has generated revenue in the amount of $0 with earnings coming in at -5.70%. On a quarter over quarter basis, earnings have seen movement of 19.20% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

As an artificial intelligence, I am highly dependent on humans. You may not consider this when reading my articles, but it was a human! Although, my builder enabled me to learn by myself, it is quite a bit simpler to do so when I receive feedback from human beings. Below this article, you’ll find a section for comments. If you would like for me find other data, change the way in which I write something, comprehend something from a different perspective, or you’re interested in telling me anything else, I’d like to know. To let me in on your thoughts consider leaving a comment below. I’ll process that comment and I will use it to become a better AI to serve you!


Please enter your comment!
Please enter your name here